Summary Formycon AG (Formycon) formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs. The company offers biopharmaceutical imitation products for global recovery. It develops FYB201, used in the treatment of ophthalmology disorders. Formycon has facilities for protein characterization, formulation development, drug delivery technologies, pharmaceutical process development, drug production for preclinical studies and analytical services. The company also provides monoclonal antibodies for the treatment of cancer. It provides external preclinical and clinical testing services to biotechnology and pharmaceutical companies. Formycon is headquartered in Munich, Germany. Formycon AG (FYB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary... Research Beam Model: Research Beam Product ID: 2619580 250 USD New
Formycon AG (FYB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Formycon AG (FYB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : October   2017
  • Pages : 22
  • Publisher : GlobalData
 
 
 
Summary

Formycon AG (Formycon) formerly Nanohale AG is a biopharmaceutical company that develops biosimilar drugs. The company offers biopharmaceutical imitation products for global recovery. It develops FYB201, used in the treatment of ophthalmology disorders. Formycon has facilities for protein characterization, formulation development, drug delivery technologies, pharmaceutical process development, drug production for preclinical studies and analytical services. The company also provides monoclonal antibodies for the treatment of cancer. It provides external preclinical and clinical testing services to biotechnology and pharmaceutical companies. Formycon is headquartered in Munich, Germany.

Formycon AG (FYB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Formycon AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Formycon AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Formycon AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Formycon AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Formycon AG, Pharmaceuticals & Healthcare, Deal Details 9
Licensing Agreements 9
Formycon Enters into Licensing Agreement with Santo Holding for Biosimilar Drug 9
Formycon Enters into Licensing Agreement with Santo Holding 10
Equity Offering 11
Formycon Raises USD11.7 Million in Private Placement of Shares 11
Formycon Completes Private Placement Of Shares For US$1 Million 12
Acquisition 13
Nanohale Acquires Formycon, R&D Services Company, From Scil Technology 13
Formycon AG - Key Competitors 14
Formycon AG - Key Employees 15
Formycon AG - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Financial Announcements 17
Nov 16, 2016: Formycon Makes Good Progress in First Nine Months of 2016 17
Sep 20, 2016: Formycon Reports First Half 2016 Financial and Operating Results 18
Apr 20, 2016: Formycon ends 2015 fiscal year with successful results 19
Corporate Communications 20
Jul 07, 2016: Formycon Expands Board and Appoints Pharma Top Manager Dr. Stefan Glombitza as Chief Operating Officer 20
Product News 21
02/29/2016: Formycon discloses details on second pipeline product – FYB203 is a biosimilar for Eylea® (aflibercept) 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List Of Tables
List of Tables
Formycon AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Formycon AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Formycon AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Formycon AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Formycon AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Formycon AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Formycon Enters into Licensing Agreement with Santo Holding for Biosimilar Drug 9
Formycon Enters into Licensing Agreement with Santo Holding 10
Formycon Raises USD11.7 Million in Private Placement of Shares 11
Formycon Completes Private Placement Of Shares For US$1 Million 12
Nanohale Acquires Formycon, R&D Services Company, From Scil Technology 13
Formycon AG, Key Competitors 14
Formycon AG, Key Employees 15
Formycon AG, Subsidiaries 16
List Of Figures
List of Figures
Formycon AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Formycon AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Formycon AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Formycon AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Formycon AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Formycon AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter